NIH's limited competition supports partnerships between resource-limited institutions and designated cancer centers to strengthen cancer research, infrastructure, training, and outreach.
Funder: National Institutes of Health
Due Dates: December 25, 2026 (Earliest submission) | January 25, 2027 (Application deadline)
Funding Amounts: Up to $1.3 million–$1.8 million in direct costs annually per partnership for up to 5 years
Summary: CAPRI supports partnerships between Resource Limited Institutions and NCI-designated Cancer Centers to strengthen cancer research, infrastructure, workforce development, and outreach.
Key Information: Each partnership must include an RLI and an NCI-designated Cancer Center, with linked applications from partnering institutions.
The National Cancer Institute (NCI), part of NIH, administers CAPRI as a limited-competition U54 cooperative agreement program. It establishes and strengthens mutually beneficial partnerships between Resource Limited Institutions (RLIs) and NCI-designated Cancer Centers. The program builds sustainable research capacity, improves institutional competitiveness, and supports Early-Stage Investigators and trainees through collaborative research, mentorship, and professional development.
Joint research projects, conducted primarily at RLIs, may span basic, clinical, translational, prevention, control, behavioral, population, and outreach research. Clinical trials are optional. Partnerships integrate research with coordinated community outreach and education, aiming to generate preliminary data for competitive R01-level applications and extend research benefits nationwide. The broader goals are to reduce cancer risk, incidence, morbidity, and mortality and improve survivors’ quality of life.